April 2012
New research establishes that benzo¬diazepines cause addiction in a way simi¬lar to that of opioids, cannabinoids, and the club drug GHB. The discovery opens the door to design¬ing new benzodiazepines that counteract anxiety but are not addictive.

NIDA Announces Avant-Garde Medication Development Awards

March 2012
Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.

In Animals, Receptor Puts Brakes on Nicotine Consumption

March 2012
New research suggests that differences in tobacco consumption reflect, in part, differences in the functional efficacy of a specific type of receptor in a pathway of the brain. In animal studies, nicotinic acetylcholine receptors with the α5 subunit played a key role in producing aversive responses to nicotine, thereby dissuading further consumption of the drug.

NIDA Notes Articles: Medication Development

Categories

Dates

2012

2011

2010

2009

2008

2007

2006

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics

Well-Known Mechanism Underlies Benzodiazepines' Addictive Properties

NIDA Announces Avant-Garde Medication Development Awards

In Animals, Receptor Puts Brakes on Nicotine Consumption

Neuropeptide Promotes Behaviors Tied to Addiction and Overeating

NIDA's Funding Priorities To Remain Constant

Medication Reduces Rats' Return to Methamphetamine Seeking

NIDA Appoints New Director of the Intramural Research Program

Modafinil Normalizes Sleep During Early Cocaine Abstinence

Three Scientists Join Advisory Council

New Tools and Strategies to Bolster Behavioral Therapy